nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—CYP2A6—Methimazole—Graves' disease	0.269	0.334	CbGbCtD
Valproic Acid—CYP2B6—Methimazole—Graves' disease	0.175	0.218	CbGbCtD
Valproic Acid—CYP2C19—Methimazole—Graves' disease	0.111	0.138	CbGbCtD
Valproic Acid—CYP1A2—Methimazole—Graves' disease	0.103	0.128	CbGbCtD
Valproic Acid—CYP2C9—Methimazole—Graves' disease	0.0926	0.115	CbGbCtD
Valproic Acid—CYP3A4—Methimazole—Graves' disease	0.0539	0.0669	CbGbCtD
Valproic Acid—Traumatic liver injury—Propylthiouracil—Graves' disease	0.011	0.101	CcSEcCtD
Valproic Acid—Erythema nodosum—Propylthiouracil—Graves' disease	0.00948	0.0867	CcSEcCtD
Valproic Acid—OGDH—eye—Graves' disease	0.00537	0.063	CbGeAlD
Valproic Acid—OGDH—connective tissue—Graves' disease	0.00517	0.0607	CbGeAlD
Valproic Acid—Liver injury—Propylthiouracil—Graves' disease	0.00487	0.0446	CcSEcCtD
Valproic Acid—HDAC9—eye—Graves' disease	0.00473	0.0555	CbGeAlD
Valproic Acid—Aplastic anaemia—Methimazole—Graves' disease	0.00453	0.0414	CcSEcCtD
Valproic Acid—Vasculitis—Propylthiouracil—Graves' disease	0.0042	0.0384	CcSEcCtD
Valproic Acid—OGDH—pituitary gland—Graves' disease	0.00398	0.0468	CbGeAlD
Valproic Acid—OGDH—adipose tissue—Graves' disease	0.00397	0.0466	CbGeAlD
Valproic Acid—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00385	0.0352	CcSEcCtD
Valproic Acid—HDAC9—adipose tissue—Graves' disease	0.0035	0.0411	CbGeAlD
Valproic Acid—OGDH—thyroid gland—Graves' disease	0.00344	0.0403	CbGeAlD
Valproic Acid—Hepatic failure—Propylthiouracil—Graves' disease	0.00331	0.0303	CcSEcCtD
Valproic Acid—ABAT—eye—Graves' disease	0.00321	0.0377	CbGeAlD
Valproic Acid—ACADSB—pituitary gland—Graves' disease	0.00317	0.0372	CbGeAlD
Valproic Acid—ACADSB—adipose tissue—Graves' disease	0.00315	0.037	CbGeAlD
Valproic Acid—HDAC9—thyroid gland—Graves' disease	0.00303	0.0355	CbGeAlD
Valproic Acid—ALDH5A1—adipose tissue—Graves' disease	0.00278	0.0326	CbGeAlD
Valproic Acid—ACADSB—thyroid gland—Graves' disease	0.00273	0.032	CbGeAlD
Valproic Acid—Drowsiness—Methimazole—Graves' disease	0.0027	0.0247	CcSEcCtD
Valproic Acid—Agranulocytosis—Methimazole—Graves' disease	0.00252	0.023	CcSEcCtD
Valproic Acid—HDAC2—eye—Graves' disease	0.00242	0.0284	CbGeAlD
Valproic Acid—ALDH5A1—thyroid gland—Graves' disease	0.0024	0.0282	CbGeAlD
Valproic Acid—ABAT—pituitary gland—Graves' disease	0.00238	0.028	CbGeAlD
Valproic Acid—ABAT—adipose tissue—Graves' disease	0.00237	0.0279	CbGeAlD
Valproic Acid—HDAC2—connective tissue—Graves' disease	0.00233	0.0274	CbGeAlD
Valproic Acid—Drowsiness—Propylthiouracil—Graves' disease	0.00229	0.021	CcSEcCtD
Valproic Acid—SLC16A1—eye—Graves' disease	0.00215	0.0252	CbGeAlD
Valproic Acid—Agranulocytosis—Propylthiouracil—Graves' disease	0.00214	0.0196	CcSEcCtD
Valproic Acid—Alopecia—Methimazole—Graves' disease	0.00214	0.0196	CcSEcCtD
Valproic Acid—Haemoglobin—Propylthiouracil—Graves' disease	0.00207	0.0189	CcSEcCtD
Valproic Acid—Haemorrhage—Propylthiouracil—Graves' disease	0.00206	0.0188	CcSEcCtD
Valproic Acid—ABAT—thyroid gland—Graves' disease	0.00206	0.0241	CbGeAlD
Valproic Acid—Vertigo—Methimazole—Graves' disease	0.00189	0.0173	CcSEcCtD
Valproic Acid—Leukopenia—Methimazole—Graves' disease	0.00189	0.0173	CcSEcCtD
Valproic Acid—Alopecia—Propylthiouracil—Graves' disease	0.00182	0.0166	CcSEcCtD
Valproic Acid—HDAC2—pituitary gland—Graves' disease	0.0018	0.0211	CbGeAlD
Valproic Acid—Myalgia—Methimazole—Graves' disease	0.00179	0.0164	CcSEcCtD
Valproic Acid—Arthralgia—Methimazole—Graves' disease	0.00179	0.0164	CcSEcCtD
Valproic Acid—HDAC2—adipose tissue—Graves' disease	0.00179	0.021	CbGeAlD
Valproic Acid—Dysgeusia—Propylthiouracil—Graves' disease	0.00175	0.0161	CcSEcCtD
Valproic Acid—Oedema—Methimazole—Graves' disease	0.00172	0.0157	CcSEcCtD
Valproic Acid—Thrombocytopenia—Methimazole—Graves' disease	0.00168	0.0154	CcSEcCtD
Valproic Acid—SLC22A8—eye—Graves' disease	0.00163	0.0191	CbGeAlD
Valproic Acid—Vertigo—Propylthiouracil—Graves' disease	0.00161	0.0147	CcSEcCtD
Valproic Acid—Leukopenia—Propylthiouracil—Graves' disease	0.0016	0.0147	CcSEcCtD
Valproic Acid—SLC16A1—pituitary gland—Graves' disease	0.0016	0.0187	CbGeAlD
Valproic Acid—SLC16A1—adipose tissue—Graves' disease	0.00159	0.0187	CbGeAlD
Valproic Acid—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00157	0.0143	CcSEcCtD
Valproic Acid—CYP2A6—adipose tissue—Graves' disease	0.00157	0.0184	CbGeAlD
Valproic Acid—HDAC2—thyroid gland—Graves' disease	0.00155	0.0182	CbGeAlD
Valproic Acid—Paraesthesia—Methimazole—Graves' disease	0.00154	0.0141	CcSEcCtD
Valproic Acid—Somnolence—Methimazole—Graves' disease	0.00153	0.014	CcSEcCtD
Valproic Acid—Arthralgia—Propylthiouracil—Graves' disease	0.00153	0.014	CcSEcCtD
Valproic Acid—Myalgia—Propylthiouracil—Graves' disease	0.00153	0.014	CcSEcCtD
Valproic Acid—Dyspepsia—Methimazole—Graves' disease	0.00151	0.0139	CcSEcCtD
Valproic Acid—Oedema—Propylthiouracil—Graves' disease	0.00146	0.0134	CcSEcCtD
Valproic Acid—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00143	0.0131	CcSEcCtD
Valproic Acid—SLC16A1—thyroid gland—Graves' disease	0.00138	0.0161	CbGeAlD
Valproic Acid—Urticaria—Methimazole—Graves' disease	0.00137	0.0125	CcSEcCtD
Valproic Acid—Body temperature increased—Methimazole—Graves' disease	0.00136	0.0124	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00133	0.0122	CcSEcCtD
Valproic Acid—Paraesthesia—Propylthiouracil—Graves' disease	0.00131	0.012	CcSEcCtD
Valproic Acid—Somnolence—Propylthiouracil—Graves' disease	0.0013	0.0119	CcSEcCtD
Valproic Acid—Dyspepsia—Propylthiouracil—Graves' disease	0.00129	0.0118	CcSEcCtD
Valproic Acid—Pruritus—Methimazole—Graves' disease	0.00122	0.0111	CcSEcCtD
Valproic Acid—Urticaria—Propylthiouracil—Graves' disease	0.00116	0.0106	CcSEcCtD
Valproic Acid—Body temperature increased—Propylthiouracil—Graves' disease	0.00116	0.0106	CcSEcCtD
Valproic Acid—Vomiting—Methimazole—Graves' disease	0.00109	0.01	CcSEcCtD
Valproic Acid—Rash—Methimazole—Graves' disease	0.00108	0.00993	CcSEcCtD
Valproic Acid—Dermatitis—Methimazole—Graves' disease	0.00108	0.00992	CcSEcCtD
Valproic Acid—Headache—Methimazole—Graves' disease	0.00108	0.00986	CcSEcCtD
Valproic Acid—Pruritus—Propylthiouracil—Graves' disease	0.00103	0.00947	CcSEcCtD
Valproic Acid—Nausea—Methimazole—Graves' disease	0.00102	0.00935	CcSEcCtD
Valproic Acid—Vomiting—Propylthiouracil—Graves' disease	0.00093	0.00851	CcSEcCtD
Valproic Acid—PTGS1—connective tissue—Graves' disease	0.000929	0.0109	CbGeAlD
Valproic Acid—Rash—Propylthiouracil—Graves' disease	0.000922	0.00844	CcSEcCtD
Valproic Acid—Dermatitis—Propylthiouracil—Graves' disease	0.000921	0.00843	CcSEcCtD
Valproic Acid—Headache—Propylthiouracil—Graves' disease	0.000916	0.00839	CcSEcCtD
Valproic Acid—SLC22A5—pituitary gland—Graves' disease	0.000912	0.0107	CbGeAlD
Valproic Acid—SLC22A5—adipose tissue—Graves' disease	0.000908	0.0107	CbGeAlD
Valproic Acid—CYP2C8—pituitary gland—Graves' disease	0.000883	0.0104	CbGeAlD
Valproic Acid—Nausea—Propylthiouracil—Graves' disease	0.000869	0.00795	CcSEcCtD
Valproic Acid—CYP3A5—adipose tissue—Graves' disease	0.000793	0.00931	CbGeAlD
Valproic Acid—SLC22A5—thyroid gland—Graves' disease	0.000786	0.00923	CbGeAlD
Valproic Acid—PTGS1—pituitary gland—Graves' disease	0.000716	0.0084	CbGeAlD
Valproic Acid—PTGS1—adipose tissue—Graves' disease	0.000713	0.00837	CbGeAlD
Valproic Acid—CYP1A2—thyroid gland—Graves' disease	0.000712	0.00836	CbGeAlD
Valproic Acid—PTGS1—thyroid gland—Graves' disease	0.000617	0.00724	CbGeAlD
